Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateWill Eli Lilly (LLY) Q2 Zepbound sales be above __?
Will Eli Lilly (LLY) Q2 Zepbound sales be above __?
BAGO
Aug 5, 2026
$4B
89%
$4.5B
75%
$5B
27%
$5.5B
13%
$6B
5%
$1,448 Vol.
$4B
$240 Vol.
89%
$4.5B
$467 Vol.
75%
$5B
$381 Vol.
27%
$5.5B
$140 Vol.
13%
$6B
$220 Vol.
5%
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Binuksan ang Market: Jul 27, 2026, 1:43 PM ET
Volume
$1,448Petsa ng Pagtatapos
Aug 5, 2026Binuksan ang Market
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$1,448Petsa ng Pagtatapos
Aug 5, 2026Binuksan ang Market
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong